White House announces most-favored-nation pricing deal with Regeneron
Regeneron joined the most-favored-nation pricing program, which ties U.S. drug prices to the lowest prices paid abroad, but the drugs and prices covered have not been disclosed [1].
The White House announced a most-favored-nation pricing deal with Regeneron on April 23, 2026, adding another manufacturer to the roster of companies that have agreed to sell medicines in the United States at prices in line with the lowest prices paid in other developed countries [1].
The announcement is listed among White House fact sheets dated April 23, 2026, under the title "Fact Sheet: President Donald J. Trump Announces Deal with Regeneron to Bring Most-Favored-Nation Pricing to American Patients" [1]. The White House has not disclosed which Regeneron medicines are covered, what they would cost, or when any new prices would take effect [1].
How the program works so far
Most-favored-nation, or MFN, pricing means patients pay prices in line with the lowest paid by other developed nations [1]. The administration launched TrumpRx.gov on February 5, 2026, as the site where patients with valid prescriptions can get those prices [1]. The launch featured drugs from the first five manufacturers to reach MFN pricing deals with the administration: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer. It covered 40 branded medicines [1].
The White House says it has announced 16 deals with major manufacturers since September 30, 2025 [1]. The initiative followed an executive order signed May 12, 2025, and letters sent to manufacturers on July 31, 2025 [1].
The GLP-1 prices already listed
The program's most-watched prices are for GLP-1 medicines. The fact sheet says the monthly price of Ozempic (semaglutide) falls from $1,028 to an average of $350, and as low as $199, depending on dosage strength [1]. Injectable Wegovy (semaglutide) falls from $1,349 to an average of $350 and as low as $199 [1]. The Wegovy pill falls from $1,349 to as low as $149, depending on strength [1]. Zepbound (tirzepatide) falls from $1,088 to an average of $346 and as low as $299, depending on strength [1]. The fact sheet does not list a price for Mounjaro (tirzepatide) [1].
The fact sheet also lists cuts for fertility medicines, including Cetrotide, which falls from $316 to $22.50, and Ovidrel, which falls from $251 to $84 [1]. Airsupra, an asthma inhaler, falls from $504 to $201, and Bevespi Aerosphere, a COPD inhaler, falls from $458 to $51 [1].
Why it matters for patients
For adults paying cash for a GLP-1, the listed prices are hundreds of dollars a month below the list prices cited in the fact sheet, though the lowest figures apply only to some dosage strengths [1]. The savings are described for patients with valid prescriptions who buy directly through TrumpRx.gov, either through coupons that can be printed or downloaded to a phone, or through channels set up by the manufacturer and integrated into the site [1].
The fact sheet does not say how these prices interact with insurance coverage or with purchases at a pharmacy counter [1]. Whether any Regeneron medicines treat diabetes or obesity has not been disclosed [1].
What happens next
The White House has said additional drugs from companies that signed MFN pricing deals will be made available through TrumpRx.gov "in the coming months," without giving dates [1]. No timeline has been disclosed for when Regeneron products would appear on the site or what they would cost [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.